Keywords: elan, posts, strong, 1st, quarter, results, ireland-based
Elan posts strong 1st quarter results
Article | 28 April 2000
Ireland-based drug-delivery specialist Elan Corp reports first-quarter2000 net income of $97.2 million, up 30% on the like-1999 quarter, on revenues of $289.5 million, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
